Insilico Medicine Selects AI Designed Obesity Drug Candidate ISM1354
Sep 30, 2026
Biotech
Superluminal Medicines Raises $60 Million for Obesity Drug Trial
Sep 3, 2026
The Series B financing will support a Phase 1 trial of a treatment for rare genetic forms of obesity by the end of 2026.
Superluminal Medicines has closed an oversubscribed $60 million Series B financing, the company announced in a press release. The round was led by BVF Partners, with participation from Deep Track Capital, Perceptive Advisors and existing investors including RA Capital Management, Insight Partners, NVIDIA and Eli Lilly and Company.
The funding will support a Phase 1 clinical trial by the end of 2026 for Superluminal's lead program, a selective MC4R agonist for rare genetic forms of obesity and hypothalamic obesity. The company said the drug selectively activates signaling pathways associated with therapeutic effects while limiting side effects.
Superluminal will also use the capital to advance other programs and expand its GPCR discovery platform for endocrine and cardiometabolic diseases. The platform combines structural biology, cryo electron microscopy, small molecule design, predictive toxicity models, machine learning and GPCR biophysics.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Funding
Oct 20 Jooba Raises $4 Million for AI Recruiting Service Oct 20 Firefly Technology Raises $20 Million for AI Safety Platform Oct 20 AuxoAI Raises $20.7 Million for Enterprise AI Consulting Oct 20 Vectorial Raises $3 Million for AI Consumer Simulations Oct 20 CBRE agrees to acquire Onnec for up to £760 millionMore from Life Sciences
Oct 20 Penn's Percival AI Flags Hidden Disease Signals in Routine CT Scans Oct 20 AstraZeneca and Oracle Partner on AI for Clinical Trials Oct 20 XRlabs Raises €7.48 Million for Surgical AI Oct 20 AI Estimates Cancer Survival From a Face Photo Oct 19 E(3)-Pose Tracks Fetal Movement During MRI ScansFree newsletter
Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Tensordyne Napier: What If One Rack Could Do the Work of Nine?
Tensordyne
This Tensordyne whitepaper presents Napier, an inference-focused AI processor and rack-scale system based on the company’s TDN Math logarithmic number system. It examines infrastructure requirements for large mixture-of-experts and agentic models, compares major inference architecture approaches, and details the TDN AIP processor, TDN72 pod, TDN Link fabric, and Napier Ultra configuration. The paper reports simulation-based performance, cost, and accuracy-validation results, including Tensordyne’s projected comparison of one Napier rack with a nine-rack Nvidia Rubin plus Groq deployment; the chip is reported as taped out and in fabrication.
Read moreYou may also like
Zealand Pharma signs AI obesity drug deal worth up to $1.2 billion
Oct 15, 2026
Biotech
LUNGevity Awards $2 Million for Lung Nodule Risk Studies
Sep 29, 2026
Healthcare
Enveda Raises $311 Million for AI Drug Discovery
Sep 24, 2026
Funding
FDA Clears Nutshell Therapeutics' NRF2 Degrader NTS231
Sep 26, 2026
Biotech
XRlabs Raises €7.48 Million for Surgical AI
Oct 20, 2026
Funding
Free, six days a week
Daily AI Brief: the AI news that matters, in your inbox.